Incyte Corporation (NASDAQ:INCY) announces that more than 60 abstracts featuring data from its ongoing clinical development program for Jakafi® (ruxolitinib) will be presented at …
Goldman Sachs analyst Salveen Richter came out today with new ratings and price targets on a handful of biotechnology stocks. Lets take a look and see what Richter …
Biopharm companies Incyte Corporatoin (NASDAQ:INCY) and LOXO Oncology (NASDAQ:LOXO) released recent successful study results. Analysts weigh in with bullish ratings on both.
Piper Jaffray analyst Joshua Schimmer weighs in on big pharma companies Celgene Corporation (NASDAQ:CELG) and Incyte Corporation (NASDAQ:INCY), maintaining a bullish outlook despite disappointing third-quarter revenues and …
As Incyte Corporation (NASDAQ:INCY) presents its findings on a pipeline drug to measure effectiveness, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) terminates its relationship …
Incyte Corporation (NASDAQ:INCY) announces the first presentation of findings from the ongoing proof-of-concept Phase 1/2 study evaluating epacadostat, Incyte’s selective IDO1 inhibitor, in combination …
Analysts came out today with an optimistic view on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Relypsa Inc (NASDAQ:RLYP), and Incyte Corporation (NASDAQ:INCY), as the iShares …
Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Company (NYSE:LLY) announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an …
Incyte Corporation (NASDAQ:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the expansion of the companies’ ongoing clinical …
Incyte Corporation (NASDAQ:INCY) announces that new data from its investigational immuno-oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) …
